Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cardiac Resynchronization Therapy · 1 trial · 1 indication
This procedure will take approximately 30 minutes prior to implant of a CRT system. At completion of this study the patient is not followed and will be transferred to another study if enrolled in a clinical or followed as a routine implant by the center.
| Arm | Type | Description |
|---|---|---|
| Cardiac Resynchronization Therapy (CRT) | EXPERIMENTAL | Implanting device to measure delays between paced chambers in heart failure patients. |
| Name | Type | Description |
|---|---|---|
| Cardiac Resynchronization Therapy | PROCEDURE | Implanting device to measure delays between paced chambers in heart failure patients. |
Inclusion Criteria: * Patient is greater than 18 years of age. * The patient or the patient's legally authorized representative is willing to give informed consent. * CRT indicated guidelines. * Patient is receiving a Medtronic IPG or ICD. Exclusion Criteria: * Patients who are pregnant. * Patien...
Top 20 of 31 competitors
Cardiac Resynchronization Therapy is an investigational treatment being studied for heart failure. It is a non-randomized, uncontrolled early Phase 1 clinical study that has been completed. The therapy is being developed by Rhythm Pharmaceuticals, Inc. for patients with heart failure.
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is developing Cardiac Resynchronization Therapy for heart failure. The company has conducted one clinical trial for this therapy, which has been completed. The trial enrolled 25 participants aged 18 years and older.
Cardiac Resynchronization Therapy is in early Phase 1 clinical development for heart failure. The therapy is investigational and not yet approved. One early Phase 1 trial has been completed, with no active trials currently ongoing.
Cardiac Resynchronization Therapy has been studied in one completed clinical trial, NCT01362465, titled "Characterization of Interventricular Conduction Measurements." This early Phase 1 trial enrolled 25 participants with heart failure and was not randomized or blinded.
Cardiac Resynchronization Therapy is not FDA approved. It is an investigational therapy in early Phase 1 clinical development for heart failure. The completed trial, NCT01362465, was an uncontrolled study that has finished, but the therapy remains in clinical development.